Fig. 5

Tumor cell priority of self-enhanced chemotherapy by AINR in vitro. A Anti-proliferation ability of different formula containing different concentration of CDDP to 4T1 cells for 24 h (n = 6). B Pt content of intracellular DNA extracted from 4T1 treated with different formula by ICP-MS. Before digestion, DNA was fixed as 100 μg (n = 3). C Western blotting assays and D Gray value analysis of γH2AX and GAPDH in 4T1 cells treated with different CDDP formulation for 24 h. E Comet assay images and F Corresponding tail DNA percentage analysis of in 4T1 cells treated with different CDDP formulation for 12 h (n = 6). The groups in B–F were that 1: Control, 2: F68@TA, 3: F68@TA@Ag, 4: CDDP, 5: F68@TA/CDDP, 6: AINR. G Survival rate of 4T1 and Hs578Bst cells treated with CDDP, F68@TA@Ag or AINR for 24 h (n = 6) H Pt content of intracellular DNA extracted from 4T1 and Hs578Bst cells treated with CDDP or AINR for 24 h by ICP-MS (n = 6). Before digestion, DNA was fixed as 100 μg. I Schematic diagram of self-enhanced chemotherapy of AINR with tumor cell priority. J Western blotting assays and K Gray value analysis of NOX4 and GAPDH in 4T1 and Hs578Bst cells. L CLSM images and M semi-quantitative analysis of H₂O₂ level in 4T1 and Hs578Bst treated with or without CDDP for 18 h (n = 10). N CLSM images and O semi-quantitative analysis of Cl.⁻ level in 4T1 and Hs578Bst cells treated with F68@TA@Ag or AINR for 12 h (n = 10). In all above experiments, the concentration of CDDP was set as 1 μg/mL. To obtain the approximately same cell uptake, incubation time for 4T1 cells and Hs578Bst cells was postponed to 12 h. The statistical analysis was performed by one-way ANOVA analysis. (ns: no significance, *p < 0.05, ** p < 0.01, *** p < 0.001)